# OnCo record springworks (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/springworks/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "springworks" ;
  schema:name "SpringWorks Therapeutics (Merck KGaA)"@en ;
  schema:description "SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025."@en ;
  schema:url <https://onco.cc/companies/springworks/>, <https://www.springworkstx.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.springworkstx.com> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:drugs <https://onco.cc/drugs/nirogacestat/> .